Walgreens Boots Alliance recently reported a $265 million loss in its fiscal first quarter, despite CEO Tim Wentworth’s optimism about the company’s progress towards a turnaround. The retail pharmacy chain has been implementing store closures and cost-cutting measures in an effort to improve its financial performance.
The $265 million quarterly loss, equivalent to 31 cents per share, marks a significant increase from the year-ago loss of $67 million or 8 cents per share. This comes at a time when Walgreens is rumored to be considering a sale to private equity firm Sycamore Partners, although the company has not confirmed these reports.
In a statement accompanying the earnings report, CEO Tim Wentworth highlighted the company’s focus on stabilizing the retail pharmacy business, optimizing its footprint, controlling costs, and improving cash flow. Despite the challenges, Wentworth expressed confidence in Walgreens’ ability to implement a sustainable operating model centered around retail pharmacy services.
The quarterly loss includes expenses related to the optimization of store locations and fair value adjustments on variable prepaid forward derivatives linked to the sale of shares in Cencora, a major drug distributor in which Walgreens holds a minority stake. Over the past three years, Walgreens has been divesting its stake in Cencora and other businesses to raise funds for debt reduction and strategic initiatives like expanding its specialty pharmacy and healthcare services offerings.
On a more positive note, Walgreens saw a 7.5% increase in sales to $39.5 billion in the first quarter, driven primarily by growth in pharmacy sales and a strong performance in the international segment. U.S. retail pharmacy sales rose by 6.6% to $30.9 billion, with a significant boost from pharmacy sales due to higher branded drug prices and prescription volume. However, retail sales in the front end of the stores declined by more than 6%, attributed to a weaker flu season and lower sales in discretionary categories.
The U.S. Healthcare segment, which includes businesses like VillageMD and CareCentrix, reported sales of $2.2 billion in the first quarter, showing growth compared to the previous year. Operating losses in this segment narrowed to $325 million from $436 million in the prior year, indicating progress in improving the financial performance of these healthcare businesses within the Walgreens portfolio.
Overall, while Walgreens continues to face challenges, the company remains focused on its turnaround efforts and is committed to building a sustainable operating model that emphasizes its retail pharmacy services.
